Project Details
Description
An investigator initiated clinical trial of combined immunotherapy (PD1-inhibitor) and irreversible electroporation in patients with metastatic pancreatic cancer.
The aim is to examine the efficacy and safety of the combined treatment.
The aim is to examine the efficacy and safety of the combined treatment.
| Short title | Electroporation Potentiated Immunotherapy in Cancer – 1.st study |
|---|---|
| Acronym | EPIC-1 |
| Status | Active |
| Effective start/end date | 01/01/2021 → 31/12/2025 |
Keywords
- pembrolizumab
- irreversible electroporation
- efficacy
- safety
- cancer
- pancreatic cancer
- pancreas
- immunotherapy
- ablation
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.